Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Secondary Progressive Multiple Sclerosis
2025-521546-23-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 43
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Remibrutinib with Placebo (2 arms). Primary endpoint: Time to 6-month confirmed disability progression (6mCDP) on Expanded Disability Status Scale (EDSS). Planned start Apr 2026; status: authorised.
02
Drugs
remibrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2025-521546-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521546-23-00.